Navigation Links
Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
Date:6/18/2009

Dr. Said Sebti, Chair, Department of Drug Discovery at Moffitt.

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses promising biological and small molecule drug candidates. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales of $2.6 billion in 2008.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com

About H. Lee Moffitt Cancer Center & Research Institute

Located in Tampa, Florida, Moffitt Cancer Center [http://www.moffitt.org/] is an NCI [http://www.cancer.gov/] Comprehensive Cancer Center - a designation that recognises Moffitt's excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network [http://www.nccn.org/index.asp], a prestigious alliance of the country's leading cancer centres, and is listed in U.S. News & World Report ['/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
2. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
3. Japanese Cancer Association and Debiopharm Honour Japanese Research
4. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
5. Debiopharm and EPFL Establish an Oncology Chair
6. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
7. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
8. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
9. Digital Healthcare Specialist Cadient Group Ranked #2 on List of Full-service Advertising Agencies in the Philadelphia Region
10. PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June
11. Cadient Group Brings Home the Gold and Two Bronze Aster Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015  Novartis is ... study of CTL019, an investigational chimeric antigen receptor ... in the treatment of specific types of hard-to-treat ... by the University of Pennsylvania,s Perelman School of ... (r/r) diffuse large B-cell lymphoma (DLBCL) and follicular ...
(Date:6/1/2015)... , June 1, 2015  The Val Skinner Foundation ... innovative science curriculum for high school students focused on ... th annual LIFE Event (LPGA Pros in the ... Country Club in West Caldwell, N.J. ... biggest stars raised more than $500,000 on Monday, bringing ...
(Date:6/1/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9kv3rl/global ... "Global Bioinformatics Market 2015-2019" report to their ... bioinformatics market to grow at a CAGR of ... a field of science that includes computational analysis ... in DNA form and protein sequences in various ...
(Date:6/1/2015)... , June 1, 2015  Boston-based Veritas Genetics ... testing industry and bring personalized medicine and prevention ... control of their health. Beginning with its first ... ovarian cancer risk, Veritas Genetics is making its ... expanding the amount of genetic data which will ...
Breaking Biology Technology:Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Val Skinner Foundation Announces Partnership With Discovery Education 2Global Bioinformatics Market 2015-2019 - Rapid Developments in Molecular Diagnostics 2Global Bioinformatics Market 2015-2019 - Rapid Developments in Molecular Diagnostics 3Veritas Genetics To Advance Precision Medicine And Disease Prevention 2Veritas Genetics To Advance Precision Medicine And Disease Prevention 3
... Genetic testing market is projected to grow at a healthy pace ... by growing incidence of genetic diseases and growing consumer awareness and ... ... CA (PRWEB) October 30, 2008 -- Genetic testing, which of-late has ...
... turned into bioethanol, a renewable fuel that can be produced ... or diesel. This gives the olive processing industry an opportunity ... in olive stones it generates every year and sets a ... from the Universities of Jan and Granada in Spain show ...
... (NYSE:,GSK) (LSE: GSK) and Genelabs Technologies, Inc. (Nasdaq: ... into a definitive agreement pursuant to which,GSK will ... 35,million) through a tender offer of $1.30 per ... effort to develop and deliver novel,therapies against the ...
Cached Biology Technology:Genetic Testing Market to Exceed $6.6 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 2Genetic Testing Market to Exceed $6.6 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 3Powered by olive stones? Turning waste stones into fuel 2GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C 2GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C 3GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C 4
(Date:5/20/2015)... OXFORD, Conn. , May 20, 2015 ... "Company") announces that its wholly owned subsidiary, 3D-ID LLC, ... contractor under Team Battelle for the biometrics technology portion ... Unrestricted Suite Contract from the Department of the Army. ... facial recognition products developed for government, law enforcement and ...
(Date:5/19/2015)... , May 19, 2015  Technology is rapidly advancing, ... and in the cloud. Passwords and their management are ... OTP and standards-based specifications such as those developed by ... use of passwords presents for BYOD, COPE, IoT, and ... biometric identity protocol. In response to ...
(Date:5/18/2015)... , May 18, 2015 Fingerprint ... sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if ... June until and including Q3 2015 and the sensors will ... . Communicated order values for 2015 hereby amount to 740 ... Q1 2015 of 140 MSEK and a number of smaller ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... oral drug therapy called fenobam has shown promising initial results ... patients with Fragile X syndrome (FXS). Findings of the ... Center and the University of California, Davis, Medical Center are ... Journal of Medical Genetics . Results ...
... Human Genome Center at Shanghai (South Center, hereafter) was ... in Shanghai. To commemorate this important event, ,which marks ... specially organize a series of mini-reviews for ,this special ... attention of the Chinese life science research workers ,to ...
... MADISON, WI, JANUARY 5, 2009 Currently, plant ... ecological risks from chemical pesticides to nontarget plants ... plants. Protection of the plant development and reproduction ... protection of animals. Past research conducted by the ...
Cached Biology News:Promising new drug being evaluated as possible treatment option for fragile X syndrome 2Human genomics in China 2Human genomics in China 3Human genomics in China 4Human genomics in China 5Human genomics in China 6Human genomics in China 7Human genomics in China 8Human genomics in China 9Human genomics in China 10Human genomics in China 11
... Arrays can be used to test the ... and sera that are commonly used as ... contains spots for 21 different protein preparations ... antibody crossreactivity and species specificity, QC of ...
... based on PI's experience in high-resolution parallel ... decade. PI Hexapods were originally used in ... over wide ranges in small step sizes. ... with 3 m minimum incremental motion (combined ...
... coating using advanced automated high throughput microplate processing equipment that ... also accommodate virtually any lot size of the following formats ... 8 and 12 well strips, ... 384 well microplate, ...
... a full length insert sequencing service for ... and fosmids. Agencourt utilizes unique library ... There are several features that allow ... with rapid turnaround including our patented magnetic ...
Biology Products: